As of 2026-07-10, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -16.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 2,044.06 mil USD. URGN's TTM EBITDA according to its financial statements is -127.23 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 10.3x | 10.2x |
| Forward P/E multiples | 9.3x - 11.7x | 11.6x |
| Fair Price | (25.96) - (28.73) | (30.19) |
| Upside | -164.5% - -171.4% | -175.0% |
| Date | EV/EBITDA |
| 2026-07-09 | -16.07 |
| 2026-07-08 | -15.22 |
| 2026-07-07 | -15.12 |
| 2026-07-06 | -14.99 |
| 2026-07-02 | -15.22 |
| 2026-07-01 | -15.19 |
| 2026-06-30 | -14.75 |
| 2026-06-29 | -14.47 |
| 2026-06-26 | -13.89 |
| 2026-06-25 | -13.83 |
| 2026-06-24 | -14.22 |
| 2026-06-23 | -14.12 |
| 2026-06-22 | -14.06 |
| 2026-06-18 | -13.52 |
| 2026-06-17 | -13.22 |
| 2026-06-16 | -12.90 |
| 2026-06-15 | -12.48 |
| 2026-06-12 | -12.04 |
| 2026-06-11 | -11.96 |
| 2026-06-10 | -11.38 |
| 2026-06-09 | -11.45 |
| 2026-06-08 | -11.10 |
| 2026-06-05 | -10.94 |
| 2026-06-04 | -11.23 |
| 2026-06-03 | -10.85 |
| 2026-06-02 | -10.82 |
| 2026-06-01 | -11.01 |
| 2026-05-29 | -11.43 |
| 2026-05-28 | -11.65 |
| 2026-05-27 | -11.89 |
| 2026-05-26 | -11.94 |
| 2026-05-22 | -11.72 |
| 2026-05-21 | -12.10 |
| 2026-05-20 | -12.23 |
| 2026-05-19 | -11.48 |
| 2026-05-18 | -11.60 |
| 2026-05-15 | -11.68 |
| 2026-05-14 | -12.03 |
| 2026-05-13 | -12.51 |
| 2026-05-12 | -12.07 |
| 2026-05-11 | -12.66 |
| 2026-05-08 | -11.92 |
| 2026-05-07 | -10.84 |
| 2026-05-06 | -10.71 |
| 2026-05-05 | -9.79 |
| 2026-05-04 | -9.58 |
| 2026-05-01 | -9.47 |
| 2026-04-30 | -9.79 |
| 2026-04-29 | -9.60 |
| 2026-04-28 | -9.90 |